These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27172895)

  • 1. High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype.
    Dennison JB; Shahmoradgoli M; Liu W; Ju Z; Meric-Bernstam F; Perou CM; Sahin AA; Welm A; Oesterreich S; Sikora MJ; Brown RE; Mills GB
    Clin Cancer Res; 2016 Oct; 22(20):5068-5078. PubMed ID: 27172895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes.
    Cid S; Eiro N; Fernández B; Sánchez R; Andicoechea A; Fernández-Muñiz PI; González LO; Vizoso FJ
    Clin Breast Cancer; 2018 Feb; 18(1):e123-e133. PubMed ID: 28927692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
    Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
    Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
    Tsang JY; Hui SW; Ni YB; Chan SK; Yamaguchi R; Kwong A; Law BK; Tse GM
    Breast Cancer Res Treat; 2014 Jan; 143(1):1-9. PubMed ID: 24272079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtypes of Breast Cancer in Lao P.D.R.: A Study in a Limited-Resource Setting.
    Luangxay T; Virachith S; Hando K; Vilayvong S; Xaysomphet P; Arounlangsy P; Phongsavan K; Mieno MN; Honma N; Kitagawa M; Sawabe M
    Asian Pac J Cancer Prev; 2019 Feb; 20(2):589-594. PubMed ID: 30806064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct nuclear receptor expression in stroma adjacent to breast tumors.
    Knower KC; Chand AL; Eriksson N; Takagi K; Miki Y; Sasano H; Visvader JE; Lindeman GJ; Funder JW; Fuller PJ; Simpson ER; Tilley WD; Leedman PJ; Graham J; Muscat GE; Clarke CL; Clyne CD
    Breast Cancer Res Treat; 2013 Nov; 142(1):211-23. PubMed ID: 24122391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
    Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
    Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered intracellular region of MUC1 and disrupted correlation of polarity-related molecules in breast cancer subtypes.
    Iizuka M; Nakanishi Y; Fuchinoue F; Maeda T; Murakami E; Obana Y; Enomoto K; Tani M; Sakurai K; Amano S; Masuda S
    Cancer Sci; 2015 Mar; 106(3):307-14. PubMed ID: 25556893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing the Relapse Potential in Different Luminal Subtypes of Breast Cancers with Functional Proteomics.
    Lin TY; Wang PW; Huang CH; Yang PM; Pan TL
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32846884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers.
    Chiu JH; Wen CS; Wang JY; Hsu CY; Tsai YF; Hung SC; Tseng LM; Shyr YM
    J Transl Med; 2017 May; 15(1):97. PubMed ID: 28472954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
    Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
    Brodsky AS; Xiong J; Yang D; Schorl C; Fenton MA; Graves TA; Sikov WM; Resnick MB; Wang Y
    BMC Cancer; 2016 Apr; 16():274. PubMed ID: 27090210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
    Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
    Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.